v3.26.1
Commitments and Contingencies (Additional Information) (Details) - USD ($)
1 Months Ended
Nov. 08, 2024
Feb. 28, 2026
Oct. 31, 2017
Mar. 31, 2026
Dec. 31, 2025
Loss Contingencies [Line Items]          
Shares issued for upfront payment   1,551,695      
License Agreement [Member]          
Loss Contingencies [Line Items]          
Shares issued for upfront payment 2,044,390        
Payments made under license agreement $ 500,000        
AstraZeneca [Member]          
Loss Contingencies [Line Items]          
Asset acquisition     $ 5,000,000    
Maximum amount     114,300,000    
AstraZeneca [Member] | License Agreement [Member]          
Loss Contingencies [Line Items]          
Asset acquisition     $ 3,000,000    
Shares issued for upfront payment     490,798    
CMOs [Member]          
Loss Contingencies [Line Items]          
Manufacturing commitments       $ 0 $ 0